Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Rotigotine Behenate ameliorates depression in Parkinson's disease through NF-κB-mediated anti-inflammation and BDNF-mediated neuroprotection.

Created on 16 Nov 2026

Authors

Mengting Wu, Zhicong Yin, Yumeng Chen, Caiyi Qin, Mengting Zheng, Ronghao Zhang, Wenjing Lv, Yuanyingzhu Liang, Jingwei Tian, Xin Yu

Published in

International immunopharmacology. Volume 191. Issue Pt 2. Pages 117696. Nov 15, 2026. Epub Nov 15, 2026.

Abstract

Depression in Parkinson's disease (DPD) is a prevalent non-motor complication that currently lacks effective targeted therapy. We established a combined MPTP/CUMS model in male C57BL/6 mice, which induced a higher incidence of depression and more stable depressive-like phenotypes than MPTP-only modeling and closely recapitulated clinical DPD pathology. Pearson correlation analysis confirmed severe dopamine (DA) and 5-hydroxytryptamine (5-HT) dysregulation predominantly in the striatum (STR) and prefrontal cortex (PFC), identifying these regions as core DPD lesion sites. Behavioral assays demonstrated that ROTB ameliorated both motor dysfunction and depressive-like behavior and restored regional neurotransmitter balance, whereas fluoxetine-included solely as an efficacy comparator for the depressive-like phenotype-did not improve motor symptoms. Mechanistically, ROTB suppressed NF-κB/NLRP3-mediated neuroinflammation and activated the BDNF/TrkB/PI3K/Akt/GSK-3β cascade, elevating synaptic protein levels and reversing dendritic spine loss. Pharmacological inhibition of the NF-κB pathway with QNZ only partially recapitulated the antidepressant effects of ROTB, indicating the existence of NF-κB-independent protective mechanisms. In summary, ROTB alleviates DPD through NF-κB-mediated anti-inflammation and BDNF-mediated neuroprotection, offering preclinical evidence for DPD therapy.

PMID:
43035072
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement